SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (11124)6/6/2017 3:56:37 PM
From: DewDiligence_on_SI  Read Replies (2) | Respond to of 12215
 
Intercept's OCA (FXR agonist) has an inferior AE and efficacy profile. But it will be first to market (is approved in Canada now).
I question whether a crappy drug like OCA will ever be approved for NASH. The early approval is for PBC, an orphan indication.



To: tuck who wrote (11124)6/6/2017 4:30:08 PM
From: Biotech Jim  Read Replies (2) | Respond to of 12215
 
I know a bit about NASH, but this discussion will prove to be helpful. I have to run now, but thought I would add this slide to the mix for discussion. From MDGL, but I will mention that a M. Erion compound at Metabasis has a somewhat similar profile, as reported by Viking this morning:

ir.vikingtherapeutics.com

I know MZ followed VKTX, perhaps he has a view on VK2809?



HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News